I think this page has been updated too:
https://www.cytodyn.com/investors/company-information
Company Profile
CytoDyn is a publicly traded clinical stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Leronlimab is being studied for oncology and inflammation, as well as other potential indications, including but not limited to HIV and MASH. Our current business strategy is the clinical development of leronlimab, which may include the following:
Conducting a Phase II study of leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer;
Conducting a Phase II study exploring leronlimab and its effects on inflammation; and
Continuing our work researching and developing a new or modified long-acting version of leronlimab.
Other programs that may be pursued include steatosis and liver fibrosis associated with MASH, either alone or as a combination therapy; and for metastatic triple-negative breast cancer with current standard of care, and/or exploring other trials with current standard of care and other cancer and immunologic indications.
I don't recall this page either, at least not in its current content (but maybe I'm suffering from memory loss, lol):
https://www.cytodyn.com/our-science
https://www.cytodyn.com/investors/company-information
Company Profile
CytoDyn is a publicly traded clinical stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Leronlimab is being studied for oncology and inflammation, as well as other potential indications, including but not limited to HIV and MASH. Our current business strategy is the clinical development of leronlimab, which may include the following:
Conducting a Phase II study of leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer;
Conducting a Phase II study exploring leronlimab and its effects on inflammation; and
Continuing our work researching and developing a new or modified long-acting version of leronlimab.
Other programs that may be pursued include steatosis and liver fibrosis associated with MASH, either alone or as a combination therapy; and for metastatic triple-negative breast cancer with current standard of care, and/or exploring other trials with current standard of care and other cancer and immunologic indications.
I don't recall this page either, at least not in its current content (but maybe I'm suffering from memory loss, lol):
https://www.cytodyn.com/our-science
6
